Does exogenous glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient in critically ill patients with pre-existing type-2 diabetes?
The effect of exogenous glucagon-like peptide-1 (GLP-1) compared to placebo on glycaemia in critically ill patients with pre-existing type-2 diabetes during small intestinal feeding
Adam Deane
10 participants
Jul 1, 2009
Interventional
Conditions
Summary
The primary objective of this study is to establish if glucagon-like peptide-1 (a hormone released from the gastrointestinal) has an effect on blood sugar levels in diabetic patients who are critically ill
Eligibility
Inclusion Criteria3
- Critically ill patients with pre-existing type- 2 diabetes (not requiring insulin prior to hospital) and who require artificial ventilation
- Likely to be ventilated for >48hrs
- Suitable to receive enteral nutrition via naso-jejunal feeding tube
Exclusion Criteria1
- Age <18 Age>85 Pregnancy Small bowel obstruction History of insulin-requiring diabetes Previous surgery on the oesophagus, stomoach or duodenum Any gastrointestinal surgery on this admission
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intravenous Glucagon-like peptide-1 (reconstituted in 4%albumin) at 1.2pmol/kg/min will be administered for 270 min at 1ml/min. The infusion will commence 30 minutes prior to the commencement of intestinal nutrient infusion. Seperated by 24 hours the cross-over treatment is placebo (intravenous 4% Albumin at 1ml/min for 270 min), again commenced 30 minutes prior to intestinal nutrient infusion
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000185066